title: Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design.
abstract: BACKGROUND
  Prophylactic platelet (PLT) transfusions are standard treatment for patients receiving high-dose chemotherapy, but the optimal dose is not known. A randomized controlled trial was undertaken to examine the effectiveness of low-dose PLT transfusions and to determine the need for further studies.
  
  
  METHODS
  Patients (n = 111) with acute leukemia or undergoing autologous peripheral blood progenitor cell (PBPC) transplantation were randomly assigned to receive low-dose (3 PLT units) or standard-dose (5 PLT units) prophylactic PLT transfusions and were monitored daily for bleeding. Using a sequential Bayesian design, the difference in major bleeding events was determined.
  
  
  RESULTS
  The percentage of patients with major bleeding events was 10.7 percent (95% credible region, 5.1%-21.2%) in the low-dose PLT group and 7.3 percent (95% credible region, 2.9%-17.2%) in the standard-dose PLT group. The two additional events in the low-dose group occurred when the PLT count exceeded 100 x 10(9) per L. There is an 89 percent probability that the absolute increase in major bleeds is less than 10 percent with low-dose PLT transfusions. The number of minor bleeding events was higher in the standard-dose group. Patients receiving low-dose PLT transfusions received 25 percent fewer PLT units. There was an 89 percent probability that low-dose transfusions reduced PLT utilization in patients with acute leukemia and a 60 percent probability in patients undergoing PBPC transplantation.
  
  
  CONCLUSIONS
  Low-dose PLT transfusions appear to be safe and effective and reduce PLT utilization. They should be further evaluated in clinical trials designed to evaluate equivalency.
authors.affiliation: Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada. atinmouth@ottawahospital.on.ca
authors.forename: Alan
authors.initials: A
authors.lastname: Tinmouth
authors.forename: Ian F
authors.initials: IF
authors.lastname: Tannock
authors.forename: Michael
authors.initials: M
authors.lastname: Crump
authors.forename: George
authors.initials: G
authors.lastname: Tomlinson
authors.forename: Joseph
authors.initials: J
authors.lastname: Brandwein
authors.forename: Mark
authors.initials: M
authors.lastname: Minden
authors.forename: David
authors.initials: D
authors.lastname: Sutton
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001499:Bayes Theorem; D005260:Female; D006470:Hemorrhage / Q000453:epidemiology; D006801:Humans; D007938:Leukemia / Q000097:blood / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D036102:Peripheral Blood Stem Cell Transplantation; D010976:Platelet Count; D017713:Platelet Transfusion; D012107:Research Design; D014182:Transplantation, Autologous